home / stock / bioaf / bioaf news

BIOAF News and Press, Bioasis Technologies Inc From 06/22/21

Stock Information
Company Name: Bioasis Technologies Inc
Stock Symbol: BIOAF
Market: OTC
Website: bioasis.us
Menu
BIOAF BIOAF Quote BIOAF Short BIOAF News BIOAF Articles BIOAF Message Board
Get BIOAF Alerts

News, Short Squeeze, Breakout and More Instantly...
BIOAF - Bioasis Technologies enters into Convertible Security Funding Agreement for Institutional Investment of up to C$10 million

NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (“ Bioasis ” or the “ Company ”) (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 TM platform t...
BIOAF - Bioasis Announces Publication Validating its xB³ (TM) Platform Technology for CNS Therapeutics

NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform te...

BIOAF - Bioasis Technologies Inc. and Aposense Enter into a Research Collaboration

NEW HAVEN, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 TM platform technology f...

BIOAF - Bioasis Announces Publication of CNS Delivery of siRNA via xB³ (TM) Platform Technology

NEW HAVEN, Conn., March 29, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform t...
BIOAF - Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing

NEW HAVEN, Conn., March 24, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF;), (“ Bioasis ” or the “ Company ”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ ...

BIOAF - Bioasis to Attend and Present at Upcoming Investor and Industry Conferences

NEW HAVEN, Conn., March 08, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform te...

BIOAF - Bioasis issues $200K of shares in a non-brokered private placement

Bioasis Technologies (BIOAF) closed a non-brokered private placement of 400K common shares to a Canadian family office at $0.50/share for gross proceeds of $200K.Shares issued in the private placement are subject to a four month hold period. For further details see: Bioasis issues $200K...
BIOAF - Bioasis Announces $200,000 Non-Brokered Private Placement

GUILFORD, Conn., Jan. 29, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-bra...

BIOAF - Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2020

GUILFORD, Conn., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 TM pla...

BIOAF - Bioasis Announces Stock Option Grant

GUILFORD, Conn., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3™ platform technology for the delivery of therapeutics across the blood-brai...
Previous 10 Next 10